Ensysce Biosciences (NASDAQ:ENSC) Announces Earnings Results, Beats Estimates By $0.21 EPS

Ensysce Biosciences (NASDAQ:ENSC) announced its quarterly earnings results on Friday. The company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.21, FiscalAI reports. Ensysce Biosciences had a negative net margin of 200.87% and a negative return on equity of 426.62%. The business had revenue of $0.96 million for the quarter, compared to analyst estimates of $1.90 million.

Ensysce Biosciences Stock Performance

ENSC traded up $0.00 on Friday, reaching $0.28. The company had a trading volume of 838,484 shares, compared to its average volume of 5,132,843. The company’s fifty day moving average is $0.48 and its 200 day moving average is $0.94. Ensysce Biosciences has a fifty-two week low of $0.23 and a fifty-two week high of $2.75. The stock has a market cap of $2.60 million, a P/E ratio of -0.07 and a beta of 0.87.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ENSC. Citadel Advisors LLC acquired a new position in shares of Ensysce Biosciences during the 3rd quarter worth approximately $34,000. Virtu Financial LLC acquired a new position in shares of Ensysce Biosciences during the 3rd quarter worth approximately $34,000. DRW Securities LLC grew its position in shares of Ensysce Biosciences by 42.4% during the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock worth $91,000 after purchasing an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in shares of Ensysce Biosciences by 100.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after purchasing an additional 75,000 shares in the last quarter. Institutional investors and hedge funds own 5.63% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.